ITD 1The first selective TGFβ inhibitor CAS# 1099644-42-4 |
- CGS 21680
Catalog No.:BCC1475
CAS No.:120225-54-9
- Preladenant
Catalog No.:BCC1868
CAS No.:377727-87-2
- Pentostatin
Catalog No.:BCC1845
CAS No.:53910-25-1
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
- LUF6000
Catalog No.:BCC1710
CAS No.:890087-21-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1099644-42-4 | SDF | Download SDF |
PubChem ID | 44135961 | Appearance | Powder |
Formula | C29H32N6O4S | M.Wt | 560.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 28 mg/mL (67.39 mM; Need ultrasonic and warming); | ||
Chemical Name | ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate | ||
SMILES | CCOC(=O)C1=C(NC2=C(C1C3=CC=C(C=C3)C4=CC=CC=C4)C(=O)CC(C2)(C)C)C | ||
Standard InChIKey | ULFUJLFTRWWLPO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C27H29NO3/c1-5-31-26(30)23-17(2)28-21-15-27(3,4)16-22(29)25(21)24(23)20-13-11-19(12-14-20)18-9-7-6-8-10-18/h6-14,24,28H,5,15-16H2,1-4H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective inhibitor of TGF-β signaling (IC50 = 0.85 μM); displays little or no inhibition of activin, Wnt or BMP signaling pathways. Induces proteasomal degradation of the TGF-β type II receptor. Inhibits TGF-β-induced mesoderm formation from mouse embryonic stem cells (ESCs) during early differentiation; selectively promotes the differentiation of ESCs to cardiomyocytes in vitro between days 3-5. Does not induce differentiation of vascular smooth muscle cells or endothelial cells. |
ITD 1 Dilution Calculator
ITD 1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7836 mL | 8.9179 mL | 17.8358 mL | 35.6716 mL | 44.5895 mL |
5 mM | 0.3567 mL | 1.7836 mL | 3.5672 mL | 7.1343 mL | 8.9179 mL |
10 mM | 0.1784 mL | 0.8918 mL | 1.7836 mL | 3.5672 mL | 4.459 mL |
50 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.7134 mL | 0.8918 mL |
100 mM | 0.0178 mL | 0.0892 mL | 0.1784 mL | 0.3567 mL | 0.4459 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
TGFβ signalling has been shown to be important at an early stage in cardiac development, with most previous investigations focussing on the role during formation of the cardiac cushions. These cushions, which develop between embryonic day E9.5 and E11.5 in the mouse, are essential precursors of the mature valves, and intimately involved in septation. It is well known that TGFβ signalling promotes endothelial to mesenchymal transition, and subsequent migration of mesenchymal cells to the cardiac jelly. ITD-1 is the first selective TGFβ inhibitor.
In vitro: ITD-1 has been used to evaluate TGFβ involvement in mesoderm formation and cardiopoietic differentiation, which occur sequentially during early development, indicating an essential role in both processes in ESC cultures. ITD-1 selectively enhanced the uncommitted mesoderm differentiation to cardiomyocytes, but not to vascular smooth muscle and endothelial cells. In summary, ITD-1 is the first selective TGFβ inhibitor and reveals an unexpected role for TGFβ signaling in controlling the differentiation of cardiomyocyte from multipotent cardiovascular precursors [1].
In vivo: So far, ITD-1 has not been subjected to conduct animal in vivo study.
Clinical trial: Up to now, ITD-1 is still in the preclinical development stage.
Reference:
[1] Willems E, Cabral-Teixeira J, Schade D, Cai W, Reeves P, Bushway PJ, Lanier M, Walsh C, Kirchhausen T, Izpisua Belmonte JC, Cashman J, Mercola M. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell. 2012 Aug 3;11(2):242-52.
- Kifunensine
Catalog No.:BCC7601
CAS No.:109944-15-2
- Sodium prasterone sulfate
Catalog No.:BCC9149
CAS No.:1099-87-2
- Granisetron
Catalog No.:BCC1601
CAS No.:109889-09-0
- CGS 9343B
Catalog No.:BCC7303
CAS No.:109826-27-9
- Kaempferol 5,7,4'-trimethyl ether
Catalog No.:BCN6587
CAS No.:1098-92-6
- Harmalidine
Catalog No.:BCN5889
CAS No.:109794-97-0
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- 9R-10alpha-Hydroxyepigambogic acid
Catalog No.:BCN3079
CAS No.:1097882-33-1
- Homopahutoxin
Catalog No.:BCN1812
CAS No.:109777-68-6
- 8 beta-(4-Acetoxy-5-hydroxytigloyloxy)costunolide
Catalog No.:BCN7123
CAS No.:109770-86-7
- cis-Dehydroosthol
Catalog No.:BCN4735
CAS No.:109741-40-4
- Murraol
Catalog No.:BCN5888
CAS No.:109741-38-0
- Succinic acid
Catalog No.:BCN5890
CAS No.:110-15-6
- Maleic acid
Catalog No.:BCN8426
CAS No.:110-16-7
- Fumaric acid
Catalog No.:BCN5989
CAS No.:110-17-8
- Sorbic acid
Catalog No.:BCN2218
CAS No.:110-44-1
- 8-O-Ethylyunaconitine
Catalog No.:BCN6260
CAS No.:110011-77-3
- Taurohyodeoxycholic Acid Sodium Salt
Catalog No.:BCC8363
CAS No.:110026-03-4
- Tussilagonone
Catalog No.:BCC8365
CAS No.:110042-38-1
- Calpain Inhibitor I, ALLN
Catalog No.:BCC1233
CAS No.:110044-82-1
- Strophantin K (mixture)
Catalog No.:BCC8256
CAS No.:11005-63-3
- 7-Hydroxy-3-(4-hydroxybenzylidene)chroman-4-one
Catalog No.:BCN1624
CAS No.:110064-50-1
- 12-Epinapelline
Catalog No.:BCN2800
CAS No.:110064-71-6
- Plerixafor (AMD3100)
Catalog No.:BCC1158
CAS No.:110078-46-1
Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin- 1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.[Pubmed:26630553]
J Med Chem. 2015 Dec 24;58(24):9625-38.
FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, we have discovered compound 18 (CHMFL-FLT3-122), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold). It significantly inhibited the proliferation of FLT3-ITD positive AML cancer cell lines MV4-11 (GI50 = 22 nM), MOLM13/14 (GI50 = 21 nM/42 nM). More importantly, 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GI50 = 11 nM versus 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity. In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase. In the in vivo studies 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity. Compound 18 might be a potential drug candidate for FLT3-ITD positive AML.
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.[Pubmed:25826077]
Oncotarget. 2015 Apr 20;6(11):9189-205.
FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in acute myeloid leukemia (AML), with the former associated with poor prognosis. Here, we show that the PI3K inhibitor GDC-0941 or the Akt inhibitor MK-2206 induced apoptosis through the mitochondria-mediated intrinsic pathway more efficiently in hematopoietic 32D cells driven by FLT3-TKD (32D/TKD) than FLT3-ITD (32D/ITD), which robustly activated STAT5. The resistance to GDC-0941 and MK-2206 was gained by expression of the constitutively activated STAT5 mutant STAT5A1*6 in 32D/TKD cells, while it was abrogated by the STAT5 inhibitor pimozide in 32D/ITD cells or FLT3-ITD-expressing human leukemic MV4-11 cells. GDC-0941 or MK-2206 induced dephosphorylation of 4EBP1 more conspicuously in 32D/TKD than in 32D/ITD, which was prevented or augmented by STAT5A1*6 or pimozide, respectively, and correlated with downregulation of the eIF4E/eIF4G complex formation and Mcl-1 expression. Furthermore, exogenous expression of Mcl-1 endowed resistance to GDC-0941 and MK-2206 on 32D/TKD cells. Finally, it was confirmed in primary AML cells with FLT3-ITD that pimozide enhanced 4EBP1 dephosphorylation and Mcl-1 downregulation to augment cytotoxicity of GDC-0941. These data suggest that the robust STAT5 activation by FLT3-ITD protects cells treated with the PI3K/Akt pathway inhibitors from apoptosis by maintaining Mcl-1 expression through the mTORC1/4EBP1/eIF4E pathway.
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.[Pubmed:26547689]
BMC Cancer. 2015 Nov 7;15:869.
BACKGROUND: Tumor-suppressor genes are inactivated by methylation in several cancers including acute myeloid leukemia (AML). Src homology-2 (SH2)-containing protein-tyrosine phosphatase 1 (SHP-1) is a negative regulator of the JAK/STAT pathway. Transcriptional silencing of SHP-1 plays a critical role in the development and progression of cancers through STAT3 activation. 5-Azacytidine (5-Aza) is a DNA methyltransferase inhibitor that causes DNA demethylation resulting in re-expression of silenced SHP-1. Lestaurtinib (CEP-701) is a multi-targeted tyrosine kinase inhibitor that potently inhibits FLT3 tyrosine kinase and induces hematological remission in AML patients harboring the internal tandem duplication of the FLT3 gene (FLT3-ITD). However, the majority of patients in clinical trials developed resistance to CEP-701. Therefore, the aim of this study, was to assess the effect of re-expression of SHP-1 on sensitivity to CEP-701 in resistant AML cells. METHODS: Resistant cells harboring the FLT3-ITD were developed by overexposure of MV4-11 to CEP-701, and the effects of 5-Aza treatment were investigated. Apoptosis and cytotoxicity of CEP-701 were determined using Annexin V and MTS assays, respectively. Gene expression was performed by quantitative real-time PCR. STATs activity was examined by western blotting and the methylation profile of SHP-1 was studied using MS-PCR and pyrosequencing analysis. Repeated-measures ANOVA and Kruskal-Wallis tests were used for statistical analysis. RESULTS: The cytotoxic dose of CEP-701 on resistant cells was significantly higher in comparison with parental and MV4-11R-cep + 5-Aza cells (p = 0.004). The resistant cells showed a significant higher viability and lower apoptosis compared with other cells (p < 0.001). Expression of SHP-1 was 7-fold higher in MV4-11R-cep + 5-Aza cells compared to parental and resistant cells (p = 0.011). STAT3 was activated in resistant cells. Methylation of SHP-1 was significantly decreased in MV4-11R-cep + 5-Aza cells (p = 0.002). CONCLUSIONS: The restoration of SHP-1 expression induces sensitivity towards CEP-701 and could serve as a target in the treatment of AML. Our findings support the hypothesis that, the tumor-suppressor effect of SHP-1 is lost due to epigenetic silencing and its re-expression might play an important role in re-inducing sensitivity to TKIs. Thus, SHP-1 is a plausible candidate for a role in the development of CEP-701 resistance in FLT3-ITD+ AML patients.